China SXT Pharmaceuticals, Inc. entered into a securities purchase agreement with an institutional investor for up to $30,000,000 in pre-paid purchases of Class A ordinary shares. The initial purchase of $3,150,000 is expected to be closed on July 6, 2026, with a 5% original issue discount and 7% annual interest. Subsequent purchases between $250,000 and $3,000,000 are permitted within a two-year commitment period. The company is a pharmaceutical company focused on developing and commercializing anti-infective drugs.